RYTM Overview

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company’s lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.

Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is140.62 USD with a low forecast of 123.00 USD and a high forecast of 167.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rhythm Pharmaceuticals Inc revenue for the last quarter amounts to 57.25M USD, increased 36.87

Rhythm Pharmaceuticals Inc. EPS for the last quarter amounts to -0.73 USD, increased 1.39

Rhythm Pharmaceuticals Inc (RYTM) has 414 emplpoyees as of March 25 2026.

Today RYTM has the market capitalization of 5.64B USD.